MNGO, a manufacturer of e-cigarettes and disposable vaping products, has revealed that it has advanced to the “filing” stage of the U.S. Food and Drug Administration’s Premarket Tobacco Product Application (PMTA) process. MNGO has become one of the first independent, family-owned companies to reach this phase of the FDA’s regulatory approval process. MNGO is now moving into the substantive review phase of the PMTA process.
In a press release, the company issued the following statement about its latest achievement:
“Our goal has always been to provide adults with the highest quality alternative products that are affordable and taste great. While PMTA represents a major investment of time and resources for MNGO, we actually welcome the work. We want the industry to comprise only companies that respect quality and customer safety as much as we do. We believe that the PMTA process is an important regulatory step for the vapor industry, and we are committed to working together with the FDA and remain optimistic about receiving a marketing order.”
For MNGO, the PMTA process has been a global effort with teams around the world working together to support the document-intensive application. The final submission to the FDA included thousands of pages of scientific research and other supporting data.
“We believe our products are appropriate for the protection of public health,” MNGO proclaimed in a press statement. “We have always been committed to creating products for adult smokers seeking an alternative to combustible cigarette smoking and hold ourselves to higher standards.”
MNGO’s products have been in the U.S. market since 2015. The company is currently preparing new PMTAs for 2021 that it plans to file for new products as part of an effort to remain sustainable in the e-cigarette industry. These new products will help MNGO remain relevant to its trusted partners and consumers for years to come.
For all the latest news from MNGO, visit mngostick.com.